UCB showcases advancements in its late stage immunology portfolio through innovative research at 2016 ACRARHP Annual Meeting

ATLANTA Nov. 11 2016 PRNewswire UCB a global biopharmaceutical company focusing on immunology neurology and bone treatments and research is proud to announce 16 CIMZIAÂ certolizumab pegol presentations at the 2016 American College of RheumatologyAssociati...